secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telesis Bio Inc. (—)
CIK:        0001850079
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038056
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Telesis Bio Q4 revenue down 26% YoY to $7.0M; net loss widens to $18.3M; BioXp kits hit record $1.0M
--------------------------------------------------------------------------------

- Revenue $7.0M in Q4 2023, down 26% YoY from $9.5M; full-year $27.5M flat.
- Net loss $18.3M ($0.61/share) vs $8.1M ($0.28) prior year Q4; includes $11.4M goodwill impairment.
- BioXp kit sales record >$1.0M in Q4, up 59.6% QoQ and 25.9% YoY; mRNA workflow sales grew >300%.
- Operating expense (excl impairment) down 24.4% to $10.8M; headcount reduced from 190 to 138.
- Cash and investments $19.3M at Dec 31, 2023; long-term notes payable $5.3M after $15M repayment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/0000950170-24-038056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850079/000095017024038056/tbio-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer